Document Type

Article

Publication Date

9-1-2016

Identifier

PMCID: PMC5103646 DOI: 10.5863/1551-6776-21.5.380

Abstract

Increasingly, children and adolescents with dyslipidemia qualify for pharmacologic intervention. As they are for adults, 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase inhibitors (statins) are the mainstay of pediatric dyslipidemia treatment when lifestyle modifications have failed. Despite the overall success of these drugs, the magnitude of variability in dose-exposure-response profiles contributes to adverse events and treatment failure. In children, the cause of treatment failures remains unclear. This review describes the updated guidelines for screening and management of pediatric dyslipidemia and statin disposition pathway to assist the provider in recognizing scenarios where alterations in dosage may be warranted to meet patients' specific needs.

Journal Title

J Pediatr Pharmacol Ther

Volume

21

Issue

5

First Page

380

Last Page

403

MeSH Keywords

Lovastatin; Simvastatin; Atorvastatin; Fluvastatin; Pravastatin; Rosuvastatin Calcium; Dyslipidemias; Pharmacokinetics; Pharmacogenetics; Pediatrics

Keywords

atorvastatin; dyslipidemia; fluvastatin; lovastatin; pediatrics; pharmacogenomics; pharmacokinetics; pravastatin; rosuvastatin; simvastatin; statin

Download

Share

COinS